A recent meta-analysis of randomised clinical trials (RCTs), led by Dr Maria García-Romero from the National Institute of Pediatrics in Mexico, supports the use of synbiotics for the treatment of atopic dermatitis (AD).
The prevalence of atopic diseases in Western countries is showing a dramatic increase. Recent epidemiological studies and experimental research suggest that gut microbiota may have a role in the development of atopic disorders. As such, prebiotic and probiotic supplements have been tested for primary prevention and/or treatment of AD. Until now, the results of isolated trials and meta-analyses using probiotics and prebiotics to prevent or treat AD have been inconsistent. Synbiotics are products that contain both probiotics and prebiotics and have also been used for either prevention or treatment of AD, but results are inconsistent.
Dr García-Romero and her team conducted a systematic review and meta-analysis to investigate the efficacy of synbiotics for primary prevention and treatment of AD. The authors included all published RCTs until October 2015. The primary outcomes were the Severity Scoring Atopic Dermatitis (SCORAD) index (treatment studies) and the incidence of AD (prevention studies). A total of 276 studies were initially identified. For the final meta-analysis, only 6 treatment studies and 2 prevention studies met the quality criteria for inclusion.
The most relevant results are summarised below:
In conclusion, the up-to-date weak evidence suggests that synbiotics may be useful in the treatment of AD, especially when using a mixed-strain probiotic component and among children aged 1 year or over.
Chang YS, Trivedi MK, Jha A, Lin YF, Dimaano L, García-Romero MT. Synbiotics for prevention and treatment of atopic dermatitis: a meta-analysis of randomized clinical trials. JAMA Pediatr. 2016; doi:10.1001/jamapediatrics.2015.3943.
Many consumers and healthcare providers are aware that certain probiotics may be beneficial ...